Dune Medical Devices announced today that the MarginProbe System will be used at the Breast Center, Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Hospital, in Munich, Germany. The Breast Center treats over 400 primary breast cancer cases annually at its two sites Maistrasse-Innenstadt and Grosshadern.
“We are excited to get started with the MarginProbe System. With currently available techniques, positive margins are a significant problem for patients,” said Professor Nadia Harbeck, Head of the Breast Center. “The amount of data supporting the use of the MarginProbe System is significant, and we look forward to offering it to our patients,” adds PD Dr. Darius Dian, the Head of Breast Surgery.
“The LMU-University Hospital in Munich is a well-known hospital around the world for the high quality of patient care offered,” says Dune’s Chief Executive Officer Dan Levangie. “By improving surgeons’ ability to detect positive margins during surgery, the MarginProbe System can significantly improve patients’ experiences being treated for breast cancer. We are excited to begin our collaboration with this influential center.” About Dune Medical Devices Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe and the US.
Dune Medical Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit www.dunemedical.com.